Rapid, quantitative diagnostic platform

BurstDX is revolutionizing point-of-need immunoassays by delivering accurate, rapid, low-cost diagnostics accessible in any setting. Our capillary-flow driven immunoassay (CaDI) platform provides laboratory-grade results in <10 minutes without the traditional lab. Today, users face a major tradeoff in immunoassay technology. Lateral flow assays (LFAs) are fast and inexpensive, but lack sensitivity and quantification. Laboratory ELISAs offer high sensitivity but require 4+ hours, specialized equipment, and trained personnel. BurstDX eliminates this tradeoff by enabling rapid, low-cost, quantitative results with >100x improved sensitivity compared to LFAs.

The CaDI platform is a fully automated, miniaturized ELISA that delivers high-sensitivity results from a single sample addition step. CaDI cartridges automate each ELISA step, including sample delivery to capture antibodies, labeled antibody binding, washing, and enzyme-driven signal amplification. Reagents embedded within the microfluidic cartridge are released sequentially and delivered to the detection zone with precisely controlled timing. CaDI cartridges are paired with an affordable chemiluminescent reader to further enhance sensitivity, detection limits, and enable precise quantification in the pg/mL range.

BurstDX offers OEM assay development, powered by CaDI, for partners seeking rapid, quantitative immunoassays for custom applications. We support assay development through concept, analytical validation, transfer to manufacturing, and commercialization.

The CaDI platform supports clinical and non-clinical applications, including human health, companion diagnostics, veterinary diagnostics, food safety, wellness, and environmental monitoring. CaDI is adaptable to a wide range of targets, including small molecules and proteins, and has been validated across sample types like saliva, blood, plasma, urine, and other aqueous solutions.